Q-omics provides the consensus-scored GLRX5 profile across patient tissues and cancer cell-line models. GLRX5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GLRX5 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, GLRX5 protein abundance shows 22,752 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where GLRX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLRX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLRX5 survival associations across molecular data types. GLRX5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLRX5 RNA expression–survival associations across cancer types. High GLRX5 expression shows unfavorable associations in HNSC, BLCA and CHOL, but favorable associations in KIRC, LGG and OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GLRX5 RNA expression.
This table summarizes GLRX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GLRX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLRX5 shows lower tumor expression in KIRC, THCA and KIRP and higher tumor expression in HNSC, BLCA and LUSC. The KIRC box plot shows higher GLRX5 RNA expression in normal versus tumor tissue (log2 FC = −1.172, t-test p < 0.001).
This table shows molecular features associated with GLRX5 in patient tissues and cancer cell lines. In patient samples, GLRX5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GLRX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and OESOPHAGUS.
